Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635217 | 1.00 | PDE9A (0.49) | PDE9AALDH1A1GPR3HSD17B10DRD2 | |
| SCHEMBL3676401 | 0.79 | AHR (0.57) | PDE9AALDH1A1GPR3HSD17B10PDE1C | |
| SCHEMBL16156592 | 0.78 | ALDH1A1 (0.44) | PDE9AALDH1A1GPR3HSD17B10DRD2 | |
| SCHEMBL8588245 | 0.78 | ALDH1A1 (0.50) | ALDH1A1GPR3HSD17B10DRD2DRD4 | |
| SCHEMBL20505152 | 0.78 | ALDH1A1 (0.44) | PDE9AALDH1A1GPR3HSD17B10DRD2 | |
| SCHEMBL9034264 | 0.78 | ALDH1A1 (0.44) | PDE9AALDH1A1GPR3HSD17B10DRD2 | |
| SCHEMBL2731190 | 0.78 | DRD2 (0.47) | PDE9AALDH1A1GPR3HSD17B10DRD2 | |
| SCHEMBL3680016 | 0.78 | AHR (0.55) | PDE9AALDH1A1GPR3HSD17B10DRD2 | |
| SCHEMBL1514832 | 0.78 | PDE9A (0.47) | PDE9AALDH1A1GPR3HSD17B10PDE1C | |
| SCHEMBL5858501 | 0.78 | PLA2G1B (0.59) | PDE9AALDH1A1GPR3HSD17B10PDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671880-B | Synthesis and application of indole-2, 3-dinitrile antitumor compounds containing fatty amino | 大连理工大学 | 2023-06-06 | — | — | CN | claimed |
| CN-114671880-A | Synthesis and application of indole-2, 3-dinitrile antitumor compound containing aliphatic amino | 大连理工大学 | 2022-06-28 | — | — | CN | claimed |
| CN-114671880-B | Synthesis and application of indole-2, 3-dinitrile antitumor compounds containing fatty amino | 大连理工大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-114671880-B | Synthesis and application of indole-2, 3-dinitrile antitumor compounds containing fatty amino | 大连理工大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-114671880-B | Synthesis and application of indole-2, 3-dinitrile antitumor compounds containing fatty amino | 大连理工大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-114671880-A | Synthesis and application of indole-2, 3-dinitrile antitumor compound containing aliphatic amino | 大连理工大学 | 2022-06-28 | — | — | CN | disclosed |
| CN-114671880-A | Synthesis and application of indole-2, 3-dinitrile antitumor compound containing aliphatic amino | 大连理工大学 | 2022-06-28 | — | — | CN | disclosed |
| CN-114671880-A | Synthesis and application of indole-2, 3-dinitrile antitumor compound containing aliphatic amino | 大连理工大学 | 2022-06-28 | — | — | CN | disclosed |
| CN-110635167-B | Nonaqueous electrolyte solution, battery containing same, and electric vehicle | 比亚迪股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-110635167-A | Nonaqueous electrolyte solution, battery containing same, and electric vehicle | 比亚迪股份有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-110483555-A | D (π-A) of the one kind based on pyrazine indoles end receptor2Type small molecule donor material and preparation method and application | UNIV CHANGZHOU | 2019-11-22 | — | — | CN | disclosed |
| US-8673948-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2079466-B1 | SUBSTITUTED INDOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | PDE9A 1725/4885ALDH1A1 671/4885GPR3 173/4885 |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | PDE9A 1725/4885ALDH1A1 671/4885GPR3 173/4885 |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | AR, NR5A1, NR3C2 | PDE9A 2254/4885ALDH1A1 3006/4885GPR3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.